Sequence Prescription and Intake Process: How It Works, What to Expect, and Whether It's Worth It

What Is Sequence and Who Owns It Now?

Sequence launched in 2021 as an independent telehealth platform focused on obesity pharmacotherapy. WW International (formerly Weight Watchers) acquired the company in 2023 and folded it into what is now called WeightWatchers Clinic. The clinical infrastructure, prescribing workflows, and provider network remain largely the same. The rebrand reflects WW's strategic pivot toward prescription weight management after the success of GLP-1 receptor agonists reshaped the obesity treatment market.

The platform connects patients with board-certified physicians, nurse practitioners, and physician assistants who hold obesity-medicine credentials. Sequence does not dispense medication itself. Prescriptions are sent to the patient's pharmacy of choice, including retail chains and compounding pharmacies, depending on medication availability and insurance status.

A 2024 retrospective analysis published in Obesity found that telehealth-initiated GLP-1 therapy produced weight-loss outcomes comparable to in-person care at 6 months, with adherence rates above 70% in structured follow-up programs [1]. That finding supports the general model Sequence uses, though the study did not evaluate Sequence specifically.

Step-by-Step Intake Process

The entire onboarding follows a four-phase workflow that typically resolves within two business days. Here is what each phase looks like.

Phase 1: Online health questionnaire. Patients complete a detailed intake form covering medical history, current medications, previous weight-loss attempts, and lifestyle factors. The questionnaire screens for contraindications to GLP-1 therapy, including personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), both of which are FDA-labeled contraindications for semaglutide and tirzepatide [2].

Phase 2: Metabolic health review. Sequence may request recent lab work (typically within the last 12 months) including HbA1c, fasting glucose, lipid panel, and thyroid function. Patients without recent labs can be directed to a partner lab network. This step helps clinicians stratify cardiovascular and metabolic risk, consistent with the 2023 American Association of Clinical Endocrinology (AACE) obesity treatment algorithm [3].

Phase 3: Clinician consultation. A licensed prescriber reviews the intake, labs, and health history. Depending on the state and provider, this consultation occurs via asynchronous messaging, phone, or synchronous video visit. The clinician discusses treatment options, sets expectations for titration schedules, and reviews potential side effects.

Phase 4: Prescription and pharmacy routing. If appropriate, the clinician sends a prescription to the patient's chosen pharmacy. Sequence supports brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) and, where legally permitted and clinically appropriate, compounded semaglutide. Patients receive a titration schedule and instructions for self-injection.

Which Medications Can Sequence Prescribe?

Sequence clinicians can prescribe any FDA-approved anti-obesity medication within their scope of practice. The most commonly prescribed agents include semaglutide 2.4 mg weekly (Wegovy) and tirzepatide up to 15 mg weekly (Zepbound). Both drugs carry strong Phase III data.

In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo [4]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieved 20.9% weight reduction at 72 weeks versus 3.1% for placebo [5]. These are the largest effect sizes ever recorded for non-surgical obesity treatments.

Sequence clinicians also prescribe oral semaglutide (Rybelsus), naltrexone-bupropion (Contrave), and phentermine-topiramate (Qsymia) when GLP-1 injectables are unavailable, contraindicated, or unaffordable. The platform does not prescribe standalone phentermine for long-term use, aligning with Endocrine Society guidelines recommending combination or GLP-1 therapy over older monotherapy options [6].

How Much Does Sequence Cost?

Sequence charges a monthly membership fee of approximately $99. That fee covers clinician access, ongoing monthly check-ins, titration management, and messaging support between visits. It does not cover the cost of medication.

Medication cost varies dramatically based on insurance coverage:

• With commercial insurance covering GLP-1s: Patient copay for Wegovy or Zepbound can range from $0 to $150/month with manufacturer savings cards.
• Without insurance coverage: Brand-name Wegovy lists at roughly $1,350/month; Zepbound at approximately $1,060/month, according to GoodRx and manufacturer pricing data [7].
• Compounded semaglutide: Some Sequence patients have accessed compounded formulations at $300 to $500/month, though FDA has issued warnings about compounded GLP-1 products regarding quality and sterility concerns [7].

The total annual out-of-pocket cost without insurance can exceed $17,000 when combining membership and brand-name medication. Patients should verify formulary coverage before committing.

Is Sequence Legit? Evaluating Clinical Credibility

Three factors determine whether a telehealth weight-loss platform meets clinical standards: prescriber qualifications, evidence-based protocols, and adequate follow-up. Sequence checks all three boxes, though with caveats.

Prescriber qualifications. Sequence states that its clinicians include board-certified physicians and advanced practice providers with obesity-medicine training. The platform participates in state medical board oversight and DEA registration requirements. This is consistent with telehealth prescribing standards outlined by the Federation of State Medical Boards [8].

Evidence-based protocols. The medication choices and titration schedules Sequence uses align with FDA-approved labeling and AACE guidelines. Semaglutide titration, for example, follows the standard 0.25 mg weekly escalation over 16 to 20 weeks to the maintenance dose of 2.4 mg [2]. Skipping titration steps increases gastrointestinal side effects, a point the 2022 AGA clinical practice guideline on pharmacotherapy for obesity emphasizes [9].

Follow-up structure. Monthly check-ins represent a minimum standard. A 2023 systematic review in The Lancet Diabetes & Endocrinology found that GLP-1 discontinuation rates exceeded 60% at 12 months in real-world settings without structured follow-up [10]. Platforms like Sequence that build in regular clinician contact may improve persistence, though no head-to-head trial has tested this hypothesis directly.

The main limitation: Sequence consultations often occur asynchronously. Patients with complex comorbidities (heart failure, chronic kidney disease stage 4+, active eating disorders) may need in-person evaluation that a messaging-based model cannot replace.

Sequence vs. Alternatives: How Does It Compare?

The GLP-1 telehealth market now includes Ro, Hims/Hers, Found, Calibrate, and direct-to-consumer options from Amazon Clinic and retail pharmacies. Key differentiators fall into three categories.

Membership structure. Sequence's $99/month is mid-range. Calibrate charges roughly $159/month with a 12-month commitment. Ro Body offers medication bundled at $99 to $399/month depending on the drug. Found charges $129/month. Hims and Hers have introduced compounded GLP-1 packages starting around $199/month including medication.

Clinical depth. Sequence (via WeightWatchers Clinic) pairs pharmacotherapy with behavioral programming from WW's legacy platform. A 2024 JAMA Network Open study (N=15,823) found that combining GLP-1 agonists with structured behavioral intervention produced 3 to 5 percentage points more weight loss at 12 months than medication alone [11]. This represents a potential advantage, though the study evaluated clinic-based behavioral therapy, not digital programs specifically.

Medication access. All major telehealth platforms prescribe brand-name GLP-1s. The differentiator is compounded semaglutide access. Following the FDA's February 2024 announcement that semaglutide was no longer on the drug shortage list, some platforms have shifted away from compounded formulations [7]. Sequence's policy on compounded GLP-1s has fluctuated with regulatory guidance.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "The best weight-loss program is the one patients actually stay on. Telehealth removes access barriers, but clinical rigor in follow-up is what separates good platforms from marketing exercises" [12].

What Happens After You Get Your Prescription?

Post-prescription management is where telehealth platforms either deliver value or become glorified prescription pads. Sequence's ongoing care model includes the following.

Titration management. Clinicians adjust doses at scheduled intervals, typically every four weeks for semaglutide and tirzepatide. The STEP-1 and SURMOUNT-1 protocols both used gradual titration to minimize nausea, vomiting, and diarrhea, the most common adverse events occurring in 40 to 50% of patients in clinical trials [4][5].

Side-effect monitoring. Gastrointestinal symptoms account for most early discontinuations. A 2023 FDA safety communication noted ongoing evaluation of neuropsychiatric signals with GLP-1 agonists, though no causal link has been established [13]. Sequence clinicians should screen for mood changes at follow-up visits.

Weight-loss plateaus. Clinical data shows weight loss typically plateaus at 60 to 72 weeks on GLP-1 therapy [4]. The decision to continue, switch agents, or taper requires clinician judgment informed by patient goals, metabolic parameters, and side-effect burden. Sequence's monthly check-in cadence provides a framework for these conversations, though patients who need more frequent contact may find the model insufficient.

Discontinuation planning. Weight regain after GLP-1 cessation is substantial. The STEP-1 extension trial showed participants regained approximately two-thirds of lost weight within one year of stopping semaglutide [14]. Long-term treatment planning, not just prescribing, is what separates comprehensive care from transactional telehealth.

Who Is a Good Candidate for the Sequence Intake?

Not every patient seeking GLP-1 therapy is well-served by an asynchronous telehealth model. Based on FDA labeling and AACE guidelines, the following criteria identify appropriate candidates [2][3]:

• BMI of 30 kg/m² or higher, or BMI of 27 kg/m² or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• No personal or family history of MTC or MEN2
• No active or recent history of pancreatitis
• No severe gastroparesis or bowel obstruction
• No active suicidal ideation or untreated severe psychiatric illness
• Willingness to commit to monthly follow-up and behavioral changes alongside medication

Patients with eGFR <15 mL/min, decompensated liver disease, or active eating disorders should pursue in-person evaluation with a specialist rather than telehealth-initiated therapy. The Endocrine Society's 2024 clinical practice guideline specifically recommends multidisciplinary team-based care for patients with BMI above 40 or those with obesity-related organ damage [6].

Limitations of the Sequence Model

No platform review is complete without identifying structural weaknesses. Three stand out.

Asynchronous care gaps. Messaging-based consultations can miss nuance. A patient reporting "some nausea" may actually be experiencing biliary-type pain requiring imaging. The American Telemedicine Association's 2023 practice guidelines recommend synchronous video visits for initial prescribing of injectable medications, a standard Sequence does not uniformly meet [15].

Insurance navigation burden. Sequence helps with prior authorizations, but the process remains patient-driven in many cases. A 2024 KFF analysis found that 40% of employer-sponsored plans explicitly excluded GLP-1 coverage for weight loss, leaving patients to manage appeals or pay out of pocket [16].

Continuity risk. The WW acquisition introduced corporate restructuring. Patients who enrolled under the original Sequence brand have reported confusion about provider continuity, billing changes, and platform transitions. Corporate ownership changes in healthcare can disrupt the patient-provider relationship, a concern the AMA Code of Medical Ethics addresses under continuity-of-care obligations [17].